Skip to content

Study · Systematic review · 2026

33 results

Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials.

Shao C, Lin H, Yu J, Chen H, Ren Y, Ren J, Zeng Y, Wu Y, Bai H, Zhang Q, Xiao X

Diabetes, metabolic syndrome and obesity : targets and therapy15 Sept 2026

PMID42763732 (opens in a new tab)PMCIDPMC13589532 (opens in a new tab)DOI10.2147/dmso.s616418 (opens in a new tab)PepBankPUB-42763732
Read at sourcePubMedAsk about this study
Jump to 33 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study33

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with overweight or obesity and type 2 diabetes, CagriSema reduced percent body weight more than semaglutide.

    In plain wordsIn adults with overweight or obesity and type 2 diabetes, CagriSema led to more weight loss than semaglutide in pooled trials.

    Peptide
    Cagrilintide
    Outcome
    DecreasePercent body weight change
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference, body weight
    −6.6%
    CagriSema vs semaglutide

    Source sentences

    Summary
    CagriSema was associated with significantly greater percentage body weight reduction compared to semaglutide [MD -6.60%; 95%CI: -8.51 to -4.68; P2 =82%]
    1 context sentence
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with overweight or obesity and type 2 diabetes, CagriSema decreased glycated hemoglobin more than semaglutide.

    In plain wordsIn adults with overweight or obesity and type 2 diabetes, CagriSema lowered glycated hemoglobin slightly more than semaglutide in pooled trials.

    Peptide
    Cagrilintide
    Outcome
    DecreasePercent HbA1c change
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference, HbA1c
    −0.09%
    CagriSema vs semaglutide

    Source sentences

    Summary
    A greater decrease in the percentage of glycated hemoglobin was also observed for CagriSema than for semaglutide [MD -0.09%; 95%CI: -0.14 to -0.04; P=0.0004; I2 =39%]
    1 context sentence
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with overweight or obesity and type 2 diabetes, CagriSema had blood pressure effects comparable to those of semaglutide.

    In plain wordsIn adults with overweight or obesity and type 2 diabetes, CagriSema lowered blood pressure about as much as semaglutide did.

    Peptide
    Cagrilintide
    Outcome
    No significant changeBlood pressure
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    CagriSema demonstrated better blood pressure control compared with cagrilintide and placebo, with effects comparable to those of semaglutide.
    1 context sentence
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).
  4. 04HumanSystematic reviewEfficacy outcome

    In adults with overweight/obesity and type 2 diabetes, adding semaglutide to cagrilintide (CagriSema) reduced percentage body weight more than cagrilintide alone (MD -8.15%).

    In plain wordsIn adults with overweight or obesity and diabetes, adding semaglutide to cagrilintide led to more weight loss than cagrilintide alone.

    Peptide
    Semaglutide
    Outcome
    DecreasePercentage body weight change
    Study

    n: not reported in source

    Comparator
    Cagrilintide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    MD body weight
    −8.15%
    CagriSema vs cagrilintide

    Source sentences

    Summary
    CagriSema was associated with significantly greater percentage body weight reduction compared to semaglutide [MD -6.60%; 95%CI: -8.51 to -4.68; P2 =82%], cagrilintide [MD -8.15%; 95%CI: -11.40 to -4.89; P2 =95%], and placebo [MD -14.30%; 95%CI: -17.41 to -11…
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).
    Summary · context
    Eight RCTs comprising 6898 participants were included.
  5. 05HumanSystematic reviewEfficacy outcome

    In adults with overweight/obesity and type 2 diabetes, adding semaglutide to cagrilintide (CagriSema) lowered glycated hemoglobin more than cagrilintide alone (MD -0.87%).

    In plain wordsIn adults with overweight or obesity and diabetes, adding semaglutide to cagrilintide lowered glycated hemoglobin more than cagrilintide alone.

    Peptide
    Semaglutide
    Outcome
    DecreasePercentage HbA1c change
    Study

    n: not reported in source

    Comparator
    Cagrilintide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    MD HbA1c
    −0.87%
    CagriSema vs cagrilintide

    Source sentences

    Summary
    A greater decrease in the percentage of glycated hemoglobin was also observed for CagriSema than for semaglutide [MD -0.09%; 95%CI: -0.14 to -0.04; P=0.0004; I2 =39%], cagrilintide [MD -0.87%; 95% CI -1.48 to -0.26; p = 0.005; I2 = 97%], and placebo [MD -1.55%; 95% CI -2.14 to…
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).
    Summary · context
    Eight RCTs comprising 6898 participants were included.
  6. 06HumanSystematic reviewEfficacy outcome

    In adults with overweight/obesity and type 2 diabetes, adding semaglutide to cagrilintide (CagriSema) gave better blood pressure control than cagrilintide alone.

    In plain wordsIn adults with overweight or obesity and diabetes, adding semaglutide to cagrilintide controlled blood pressure better than cagrilintide alone.

    Peptide
    Semaglutide
    Outcome
    DecreaseBlood pressure
    Study

    n: not reported in source

    Comparator
    Cagrilintide
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    CagriSema demonstrated better blood pressure control compared with cagrilintide and placebo, with effects comparable to those of semaglutide.
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).
    Summary · context
    Eight RCTs comprising 6898 participants were included.
  7. 07HumanSystematic reviewEfficacy outcome

    In adults with overweight/obesity and type 2 diabetes, adding semaglutide to cagrilintide (CagriSema) decreased C-reactive protein more than cagrilintide alone.

    In plain wordsIn adults with overweight or obesity and diabetes, adding semaglutide to cagrilintide lowered C-reactive protein more than cagrilintide alone.

    Peptide
    Semaglutide
    Outcome
    DecreaseC-reactive protein
    Study

    n: not reported in source

    Comparator
    Cagrilintide
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, CagriSema significantly decreased C-reactive protein and improved lipid profiles compared with cagrilintide and placebo.
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).
    Summary · context
    Eight RCTs comprising 6898 participants were included.
  8. 08HumanSystematic reviewEfficacy outcome

    In adults with overweight/obesity and type 2 diabetes, adding semaglutide to cagrilintide (CagriSema) improved lipid profiles more than cagrilintide alone.

    In plain wordsIn adults with overweight or obesity and diabetes, adding semaglutide to cagrilintide improved blood fats more than cagrilintide alone.

    Peptide
    Semaglutide
    Outcome
    MixedLipid profile
    Study

    n: not reported in source

    Comparator
    Cagrilintide
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, CagriSema significantly decreased C-reactive protein and improved lipid profiles compared with cagrilintide and placebo.
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).
    Summary · context
    Eight RCTs comprising 6898 participants were included.

Studies that did not test the peptide alone25

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 09HumanNot a test of Cagrilintide aloneSystematic reviewEfficacy outcome

    In adults with overweight or obesity and type 2 diabetes, CagriSema reduced percent body weight more than cagrilintide.

    In plain wordsIn adults with overweight or obesity and type 2 diabetes, CagriSema led to more weight loss than cagrilintide alone in pooled trials.

    Peptide
    Cagrilintide
    Outcome
    DecreasePercent body weight change
    Study

    n: not reported in source

    Comparator
    Cagrilintide
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Mean difference, body weight
    −8.15%
    CagriSema vs cagrilintide

    Source sentences

    Summary
    CagriSema was associated with significantly greater percentage body weight reduction compared to semaglutide [MD -6.60%; 95%CI: -8.51 to -4.68; P2 =82%], cagrilintide [MD -8.15%; 95%CI: -11.40 to -4.89; P2 =95%], and placebo [MD -14.30%; 95%CI: -17.41 to -11…
    1 context sentence
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  2. 10HumanNot a test of Cagrilintide aloneSystematic reviewEfficacy outcome

    In adults with overweight or obesity and type 2 diabetes, CagriSema reduced percent body weight more than placebo.

    In plain wordsIn adults with overweight or obesity and type 2 diabetes, CagriSema led to more weight loss than placebo in pooled trials.

    Peptide
    Cagrilintide
    Outcome
    DecreasePercent body weight change
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Mean difference, body weight
    −14.3%
    CagriSema vs placebo

    Source sentences

    Summary
    CagriSema was associated with significantly greater percentage body weight reduction compared to semaglutide [MD -6.60%; 95%CI: -8.51 to -4.68; P2 =82%], cagrilintide [MD -8.15%; 95%CI: -11.40 to -4.89; P2 =95%], and placebo [MD -14.30%; 95%CI: -17.41 to -11…
    1 context sentence
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  3. 11HumanNot a test of Cagrilintide aloneSystematic reviewEfficacy outcome

    In adults with overweight or obesity and type 2 diabetes, CagriSema decreased glycated hemoglobin more than cagrilintide.

    In plain wordsIn adults with overweight or obesity and type 2 diabetes, CagriSema lowered glycated hemoglobin more than cagrilintide alone in pooled trials.

    Peptide
    Cagrilintide
    Outcome
    DecreasePercent HbA1c change
    Study

    n: not reported in source

    Comparator
    Cagrilintide
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Mean difference, HbA1c
    −0.87%
    CagriSema vs cagrilintide

    Source sentences

    Summary
    A greater decrease in the percentage of glycated hemoglobin was also observed for CagriSema than for semaglutide [MD -0.09%; 95%CI: -0.14 to -0.04; P=0.0004; I2 =39%], cagrilintide [MD -0.87%; 95% CI -1.48 to -0.26; p = 0.005; I2 = 97%], and placebo [MD -1.55%; 95% CI -2.14 to…
    1 context sentence
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  4. 12HumanNot a test of Cagrilintide aloneSystematic reviewEfficacy outcome

    In adults with overweight or obesity and type 2 diabetes, CagriSema decreased glycated hemoglobin more than placebo.

    In plain wordsIn adults with overweight or obesity and type 2 diabetes, CagriSema lowered glycated hemoglobin more than placebo in pooled trials.

    Peptide
    Cagrilintide
    Outcome
    DecreasePercent HbA1c change
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Mean difference, HbA1c
    −1.55%
    CagriSema vs placebo

    Source sentences

    Summary
    A greater decrease in the percentage of glycated hemoglobin was also observed for CagriSema than for semaglutide [MD -0.09%; 95%CI: -0.14 to -0.04; P=0.0004; I2 =39%], cagrilintide [MD -0.87%; 95% CI -1.48 to -0.26; p = 0.005; I2 = 97%], and placebo [MD -1.55%; 95% CI -2.14 to…
    1 context sentence
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  5. 13HumanNot a test of Cagrilintide aloneSystematic reviewEfficacy outcome

    In adults with overweight or obesity and type 2 diabetes, CagriSema achieved significantly greater reductions in absolute body weight across all comparators (all p < 0.0001).

    In plain wordsIn adults with overweight or obesity and type 2 diabetes, CagriSema lowered body weight in kilograms more than semaglutide, cagrilintide or placebo.

    Peptide
    Cagrilintide
    Outcome
    DecreaseAbsolute body weight
    Study

    n: not reported in source

    Comparator
    Semaglutide, cagrilintide and placebo
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Furthermore, CagriSema achieved significantly greater reductions in absolute body weight
    2 context sentences
    Summary · context
    across all comparators (all p < 0.0001).
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  6. 14HumanNot a test of Cagrilintide aloneSystematic reviewEfficacy outcome

    In adults with overweight or obesity and type 2 diabetes, CagriSema achieved significantly greater reductions in waist circumference across all comparators (all p < 0.0001).

    In plain wordsIn adults with overweight or obesity and type 2 diabetes, CagriSema reduced waist size more than semaglutide, cagrilintide or placebo.

    Peptide
    Cagrilintide
    Outcome
    DecreaseWaist circumference
    Study

    n: not reported in source

    Comparator
    Semaglutide, cagrilintide and placebo
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Furthermore, CagriSema achieved significantly greater reductions in absolute body weight, waist circumference and body mass index across all comparators (all p < 0.0001).
    1 context sentence
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  7. 15HumanNot a test of Cagrilintide aloneSystematic reviewEfficacy outcome

    In adults with overweight or obesity and type 2 diabetes, CagriSema achieved significantly greater reductions in body mass index across all comparators (all p < 0.0001).

    In plain wordsIn adults with overweight or obesity and type 2 diabetes, CagriSema lowered body mass index more than semaglutide, cagrilintide or placebo.

    Peptide
    Cagrilintide
    Outcome
    DecreaseBody mass index
    Study

    n: not reported in source

    Comparator
    Semaglutide, cagrilintide and placebo
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Furthermore, CagriSema achieved significantly greater reductions in absolute body weight, waist circumference and body mass index across all comparators (all p < 0.0001).
    1 context sentence
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  8. 16HumanNot a test of Cagrilintide aloneSystematic reviewEfficacy outcome

    In adults with overweight or obesity and type 2 diabetes, CagriSema showed better blood pressure control than cagrilintide and placebo.

    In plain wordsIn adults with overweight or obesity and type 2 diabetes, CagriSema controlled blood pressure better than cagrilintide alone or placebo.

    Peptide
    Cagrilintide
    Outcome
    DecreaseBlood pressure
    Study

    n: not reported in source

    Comparator
    Cagrilintide and placebo
    Outcome group
    Blood pressure · Cardiovascular

    Source sentences

    Summary
    CagriSema demonstrated better blood pressure control compared with cagrilintide and placebo, with effects comparable to those of semaglutide.
    1 context sentence
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  9. 17HumanNot a test of Cagrilintide aloneSystematic reviewEfficacy outcome

    In adults with overweight or obesity and type 2 diabetes, CagriSema significantly decreased C-reactive protein compared with cagrilintide and placebo.

    In plain wordsIn adults with overweight or obesity and type 2 diabetes, CagriSema lowered the inflammation marker CRP more than cagrilintide alone or placebo.

    Peptide
    Cagrilintide
    Outcome
    DecreaseC-reactive protein
    Study

    n: not reported in source

    Comparator
    Cagrilintide and placebo
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    Moreover, CagriSema significantly decreased C-reactive protein
    2 context sentences
    Summary · context
    compared with cagrilintide and placebo.
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  10. 18HumanNot a test of Cagrilintide aloneSystematic reviewEfficacy outcome

    In adults with overweight or obesity and type 2 diabetes, CagriSema improved lipid profiles compared with cagrilintide and placebo.

    In plain wordsIn adults with overweight or obesity and type 2 diabetes, CagriSema improved blood fat levels more than cagrilintide alone or placebo.

    Peptide
    Cagrilintide
    Outcome
    Direction not reportedLipid profile
    Study

    n: not reported in source

    Comparator
    Cagrilintide and placebo
    Outcome group
    Lipids · Metabolic and weight

    Source sentences

    Summary
    Moreover, CagriSema significantly decreased C-reactive protein and improved lipid profiles compared with cagrilintide and placebo.
    1 context sentence
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  11. 19HumanNot a test of Cagrilintide aloneSystematic reviewSafety outcome

    In adults with overweight or obesity and type 2 diabetes, CagriSema increased any adverse events compared with all comparators.

    In plain wordsIn adults with overweight or obesity and type 2 diabetes, CagriSema caused more side effects overall than semaglutide, cagrilintide or placebo.

    Peptide
    Cagrilintide
    Outcome
    IncreaseAny adverse events
    Study

    n: not reported in source

    Comparator
    Semaglutide, cagrilintide and placebo
    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    CagriSema increased any adverse events and gastrointestinal adverse events compared with all comparators.
    1 context sentence
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  12. 20HumanNot a test of Cagrilintide aloneSystematic reviewSafety outcome

    In adults with overweight or obesity and type 2 diabetes, CagriSema increased gastrointestinal adverse events compared with all comparators.

    In plain wordsIn adults with overweight or obesity and type 2 diabetes, CagriSema caused more stomach and bowel side effects than semaglutide, cagrilintide or placebo.

    Peptide
    Cagrilintide
    Outcome
    IncreaseGastrointestinal adverse events
    Study

    n: not reported in source

    Comparator
    Semaglutide, cagrilintide and placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    CagriSema increased any adverse events and gastrointestinal adverse events compared with all comparators.
    1 context sentence
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  13. 21HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with overweight/obesity and type 2 diabetes, CagriSema reduced percentage body weight more than semaglutide alone (MD -6.60%).

    In plain wordsIn adults with overweight or obesity and diabetes, CagriSema led to more weight loss than semaglutide alone.

    Peptide
    Semaglutide
    Outcome
    DecreasePercentage body weight change
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    MD body weight
    −6.6%
    CagriSema vs semaglutide

    Source sentences

    Summary
    CagriSema was associated with significantly greater percentage body weight reduction compared to semaglutide [MD -6.60%; 95%CI: -8.51 to -4.68; P2 =82%], cagrilintide [MD -8.15%; 95%CI: -11.40 to -4.89; P2 =95%], and placebo [MD -14.30%; 95%CI: -17.41 to -11…
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).
    Summary · context
    Eight RCTs comprising 6898 participants were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  14. 22HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with overweight/obesity and type 2 diabetes, CagriSema reduced percentage body weight more than placebo (MD -14.30%).

    In plain wordsIn adults with overweight or obesity and diabetes, CagriSema led to more weight loss than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreasePercentage body weight change
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    MD body weight
    −14.3%
    CagriSema vs placebo

    Source sentences

    Summary
    CagriSema was associated with significantly greater percentage body weight reduction compared to semaglutide [MD -6.60%; 95%CI: -8.51 to -4.68; P2 =82%], cagrilintide [MD -8.15%; 95%CI: -11.40 to -4.89; P2 =95%], and placebo [MD -14.30%; 95%CI: -17.41 to -11…
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).
    Summary · context
    Eight RCTs comprising 6898 participants were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  15. 23HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with overweight/obesity and type 2 diabetes, CagriSema lowered glycated hemoglobin more than semaglutide alone (MD -0.09%).

    In plain wordsIn adults with overweight or obesity and diabetes, CagriSema lowered glycated hemoglobin slightly more than semaglutide alone.

    Peptide
    Semaglutide
    Outcome
    DecreasePercentage HbA1c change
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    MD HbA1c
    −0.09%
    CagriSema vs semaglutide

    Source sentences

    Summary
    A greater decrease in the percentage of glycated hemoglobin was also observed for CagriSema than for semaglutide [MD -0.09%; 95%CI: -0.14 to -0.04; P=0.0004; I2 =39%], cagrilintide [MD -0.87%; 95% CI -1.48 to -0.26; p = 0.005; I2 = 97%], and placebo [MD -1.55%; 95% CI -2.14 to…
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).
    Summary · context
    Eight RCTs comprising 6898 participants were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  16. 24HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with overweight/obesity and type 2 diabetes, CagriSema lowered glycated hemoglobin more than placebo (MD -1.55%).

    In plain wordsIn adults with overweight or obesity and diabetes, CagriSema lowered glycated hemoglobin more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreasePercentage HbA1c change
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    MD HbA1c
    −1.55%
    CagriSema vs placebo

    Source sentences

    Summary
    A greater decrease in the percentage of glycated hemoglobin was also observed for CagriSema than for semaglutide [MD -0.09%; 95%CI: -0.14 to -0.04; P=0.0004; I2 =39%], cagrilintide [MD -0.87%; 95% CI -1.48 to -0.26; p = 0.005; I2 = 97%], and placebo [MD -1.55%; 95% CI -2.14 to…
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).
    Summary · context
    Eight RCTs comprising 6898 participants were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  17. 25HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with overweight/obesity and type 2 diabetes, CagriSema reduced absolute body weight more than all comparators (p < 0.0001).

    In plain wordsIn adults with overweight or obesity and diabetes, CagriSema reduced body weight more than each comparison treatment.

    Peptide
    Semaglutide
    Outcome
    DecreaseAbsolute body weight
    Study

    n: not reported in source

    Comparator
    All comparators pooled
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Furthermore, CagriSema achieved significantly greater reductions in absolute body weight, waist circumference and body mass index across all comparators (all p < 0.0001).
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).
    Summary · context
    Eight RCTs comprising 6898 participants were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  18. 26HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with overweight/obesity and type 2 diabetes, CagriSema reduced waist circumference more than all comparators (p < 0.0001).

    In plain wordsIn adults with overweight or obesity and diabetes, CagriSema reduced waist size more than each comparison treatment.

    Peptide
    Semaglutide
    Outcome
    DecreaseWaist circumference
    Study

    n: not reported in source

    Comparator
    All comparators pooled
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Furthermore, CagriSema achieved significantly greater reductions in absolute body weight, waist circumference and body mass index across all comparators (all p < 0.0001).
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).
    Summary · context
    Eight RCTs comprising 6898 participants were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  19. 27HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with overweight/obesity and type 2 diabetes, CagriSema reduced body mass index more than all comparators (p < 0.0001).

    In plain wordsIn adults with overweight or obesity and diabetes, CagriSema reduced BMI more than each comparison treatment.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody mass index
    Study

    n: not reported in source

    Comparator
    All comparators pooled
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Furthermore, CagriSema achieved significantly greater reductions in absolute body weight, waist circumference and body mass index across all comparators (all p < 0.0001).
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).
    Summary · context
    Eight RCTs comprising 6898 participants were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  20. 28HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with overweight/obesity and type 2 diabetes, CagriSema had blood pressure effects comparable to semaglutide alone.

    In plain wordsIn adults with overweight or obesity and diabetes, CagriSema controlled blood pressure about as well as semaglutide alone.

    Peptide
    Semaglutide
    Outcome
    No significant changeBlood pressure
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Blood pressure · Cardiovascular

    Source sentences

    Summary
    CagriSema demonstrated better blood pressure control compared with cagrilintide and placebo, with effects comparable to those of semaglutide.
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).
    Summary · context
    Eight RCTs comprising 6898 participants were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  21. 29HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with overweight/obesity and type 2 diabetes, CagriSema gave better blood pressure control than placebo.

    In plain wordsIn adults with overweight or obesity and diabetes, CagriSema controlled blood pressure better than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseBlood pressure
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular

    Source sentences

    Summary
    CagriSema demonstrated better blood pressure control compared with cagrilintide and placebo, with effects comparable to those of semaglutide.
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).
    Summary · context
    Eight RCTs comprising 6898 participants were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  22. 30HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with overweight/obesity and type 2 diabetes, CagriSema decreased C-reactive protein more than placebo.

    In plain wordsIn adults with overweight or obesity and diabetes, CagriSema lowered C-reactive protein more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseC-reactive protein
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    Moreover, CagriSema significantly decreased C-reactive protein and improved lipid profiles compared with cagrilintide and placebo.
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).
    Summary · context
    Eight RCTs comprising 6898 participants were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  23. 31HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with overweight/obesity and type 2 diabetes, CagriSema improved lipid profiles more than placebo.

    In plain wordsIn adults with overweight or obesity and diabetes, CagriSema improved blood fats more than placebo.

    Peptide
    Semaglutide
    Outcome
    MixedLipid profile
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight

    Source sentences

    Summary
    Moreover, CagriSema significantly decreased C-reactive protein and improved lipid profiles compared with cagrilintide and placebo.
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).
    Summary · context
    Eight RCTs comprising 6898 participants were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  24. 32HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In adults with overweight/obesity and type 2 diabetes, CagriSema increased any adverse events compared with all comparators.

    In plain wordsIn adults with overweight or obesity and diabetes, CagriSema caused more adverse events than the comparison treatments.

    Peptide
    Semaglutide
    Outcome
    IncreaseAny adverse events
    Study

    n: not reported in source

    Comparator
    All comparators pooled
    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    CagriSema increased any adverse events and gastrointestinal adverse events compared with all comparators.
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).
    Summary · context
    Eight RCTs comprising 6898 participants were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  25. 33HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In adults with overweight/obesity and type 2 diabetes, CagriSema increased gastrointestinal adverse events compared with all comparators.

    In plain wordsIn adults with overweight or obesity and diabetes, CagriSema caused more stomach and gut adverse events than the comparison treatments.

    Peptide
    Semaglutide
    Outcome
    IncreaseGastrointestinal adverse events
    Study

    n: not reported in source

    Comparator
    All comparators pooled
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    CagriSema increased any adverse events and gastrointestinal adverse events compared with all comparators.
    2 context sentences
    Summary · context
    To evaluate the efficacy and safety of dual-agonist CagriSema vs semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight/obese status and type 2 diabetes, we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs).
    Summary · context
    Eight RCTs comprising 6898 participants were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 3 to 38Current

    28 Oct 2026, 02:04 UTC

    The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.